Abstract 2115
Background
Epithelial Growth Factor Receptor (EGFR), a type of the ERBB receptor tyrosine kinase, associated with cell survival and proliferation has properties to activate tumorigenesis and metastasis in cancer. Normally, EGFR is expressed in normal tissues such like other tyrosine kinase receptors especially in epithelial cell type tissues. In various cancer types, EGFR amplification or overexpression is commonly detected in cancer cells compared with normal epithelial tissues, and so known as a still promising therapeutic biomarker for cancer therapy in colorectal cancer, Lung cancer, gastric cancer and glioblastoma. However, several EGFR targeted therapy failed in clinical trial for cancer patients include glioblastoma and hard to find responder group in cancer patients.
Methods
To figure out clinical criteria for cancer patients, we tested a novel EGFR targeted antibody (GC1118) in glioblastoma patient-derived xenograft (PDX) models and patient-derived cell (PDC) with its genomic data.
Results
Through Xeno Trial, a method using a small scale of mice per treatment to enable the investigation of efficacy in substantially larger panels of PDX models, and it implies that therapeutic response is expected to be evident in EGFR amplification in brain tumors, in addition to efficacy was also observed in patients with EGFR amplification via High Throughput Screening (HTS). Through High Throughput Screening using glioblastoma patient-derived cells shown that cell growth inhibition in EGFR amplify cases by GC1118. In Xeno trail, inhibitory effects of tumor growth observed in EGFR amplification PDX models by GC1118 treatment as well.
Conclusions
Overall, this study results suggest that EGFR amplification status is still one of the important criteria to find responder group in glioblastoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea. (HI14C3418).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4021 - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Presenter: Paolo Nuciforo
Session: Poster Display session 3
Resources:
Abstract
5603 - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Presenter: Vinay Mittal
Session: Poster Display session 3
Resources:
Abstract
4952 - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Presenter: Kang Kook Lee
Session: Poster Display session 3
Resources:
Abstract
4590 - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Presenter: Michele Ghidini
Session: Poster Display session 3
Resources:
Abstract
3696 - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma
Presenter: Filip Janku
Session: Poster Display session 3
Resources:
Abstract
4295 - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Presenter: Daniela Di Giacomo
Session: Poster Display session 3
Resources:
Abstract
2214 - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)
Presenter: Mausumee Guha
Session: Poster Display session 3
Resources:
Abstract
5044 - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.
Presenter: Bram Agema
Session: Poster Display session 3
Resources:
Abstract
3293 - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study
Presenter: Vincenzo Quagliariello
Session: Poster Display session 3
Resources:
Abstract
3324 - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer
Presenter: Xuelu Li
Session: Poster Display session 3
Resources:
Abstract